Information for Patients and Physicians

Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma (NHL) that also expresses CD30. Brentuximab vedotin is comprised of an anti-CD30 monoclonal antibody linked to a potent cell-killing agent, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE, an antimicrotubule agent, upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect. Find more information in our Pipeline section.

BRENTUXIMAB VEDOTIN CLINICAL TRIALS CURRENTLY ENROLLING
Phase III AETHERA trial for Hodgkin lymphoma

Randomized, double-blind trial evaluating brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant

See study details ›

Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas

Evaluating the activity and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

See study details ›

Phase II trial for CD30-positive non-lymphoma malignancies

Single-agent trial assessing the antitumor activity and safety as well as the relationship of CD30 expression with antitumor activity of brentuximab vedotin in patients with CD30-positive non-lymphoma malignancies, including mulitple myeloma, leukemia and solid tumors, who have failed, refused or have been deemed ineligible for standard therapy
See study details ›

Phase II trial for retreatment of patients who previously participated in a brentuximab vedotin study

Evaluating the potential for retreatment with brentuximab vedotin in patients who have relapsed after discontinuing previous brentuximab vedotin therapy.

See study details ›

Phase I trial for front-line treatment of Hodgkin lymphoma in combination with multi-agent chemotherapy

Evaluating the safety of brentuximab vedotin in combination with multi-agent chemotherapy in newly diagnosed Hodgkin lymphoma patients; enrollment to this trial is complete

See study details ›

Phase I trial for front-line treatment of CD30-positive mature T-cell malignancies

Evaluating safety of brentuximab vedotin when administered sequentially and combined with multi-agent chemotherapy as front-line therapy in newly diagnosed patients with CD30-positive mature T-cell malignancies

See study details ›

BRENTUXIMAB VEDOTIN PATIENT RESOURCES

If you have questions about the brentuximab vedotin clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.

Privacy Policy  |  Legal Notice